Abstract
Recovery of amino acid (AA) metabolism and the associated clinical implications in chronic hepatitis C (CHC) patients with sustained virological response (SVR) following anti-hepatitis C virus (HCV) therapy remains elusive. A prospective cohort study was conducted on 222 CHC patients with SVR. Eighty-two age-matched male genotype 1 (G1) and G2 patients underwent paired serum metabolomics analyses with liquid chromatography–tandem mass spectrometry to examine AAs before and 24 weeks after anti-HCV therapy. Before anti-HCV therapy, G1 patients had a higher HCV RNA level than G2 patients. Twenty-four weeks post-therapy versus pre-therapy, repeated-measures ANOVA showed that the levels of alanine aminotransferase and most AAs decreased while those of lipids, glutamine and putrescine increased in CHC patients. The methionine sulfoxide/methionine ratio decreased, while the asymmetric dimethylarginine/arginine, glutamine/glutamate, citrulline/arginine, ornithine/arginine, kynurenine/tryptophan, tyrosine/phenylalanine and Fisher’s ratios increased. Genotype-specific subgroup analyses showed that valine and serotonin/tyrosine increased in G1 and that kynurenine and tyrosine/phenylalanine increased and sarcosine decreased in G2 patients. Viral clearance in CHC patients pan-genotypically restored fuel utilization by decelerating the tricarboxylic acid cycle. Following improvement in liver function, the urea, nitric oxide, methionine, and polyamine cycles were accelerated. The cardiometabolic risk attenuated, but the augmented kynurenine pathway activity could increase the oncogenesis risk. The trends in neurotransmitter formation differed between G1 and G2 patients after SVR. Moreover, the HCV-suppressing effect of valine was evident in G1 patients; with the exception of prostate cancer, the oncogenesis risk increased, particularly in G2 patients, at least within 24 weeks post-anti-HCV therapy.
Similar content being viewed by others
References
Babudieri S, Soddu A, Nieddu P, Tanca A, Madeddu G, Addis MF, Pagnozzi D, Cossu-Rocca P, Massarelli G, Dore MP, Uzzau S, Mura MS (2013) Proteomic characterization of hepatitis C eradication: enzyme switch in the healing liver. J Clin Virol 57:274–278
Baniasadi H, Gowda GA, Gu H, Zeng A, Zhuang S, Skill N, Maluccio M, Raftery D (2013) Targeted metabolic profiling of hepatocellular carcinoma and hepatitis C using LC-MS/MS. Electrophoresis 34:2910–2917
Bladowska J, Zimny A, Knysz B, Małyszczak K, Kołtowska A, Szewczyk P, Gąsiorowski J, Furdal M, Sąsiadek MJ (2013) Evaluation of early cerebral metabolic, perfusion and microstructural changes in HCV-positive patients: a pilot study. J Hepatol 59:651–657
Boulet MM, Chevrier G, Grenier-Larouche T, Pelletier M, Nadeau M, Scarpa J, Prehn C, Marette A, Adamski J, Tchernof A (2015) Alterations of plasma metabolite profiles related to adipose tissue distribution and cardiometabolic risk. Am J Physiol Endocrinol Metab 309:E736–E746
Breuillard C, Cynober L, Moinard C (2015) Citrulline and nitrogen homeostasis: an overview. Amino Acids 47:685–691
Burgess DJ (2013) Metabolism: glutamine connections. Nat Rev Cancer 13:293
Chang ML (2016) Metabolic alterations and hepatitis C: from bench to bedside. World J Gastroenterol 22:1461–1476
Chang ML, Tsou YK, Hu TH, Lin CH, Lin WR, Sung CM, Chen TH, Cheng ML, Chang KC, Chiu CT, Yeh CT, Pang JH, Shiao MS (2014) Distinct patterns of the lipid alterations between genotype 1 and 2 chronic hepatitis C patients after viral clearance. PLoS One 9:e104783
Chang ML, Liang KH, Ku CL, Lo CC, Cheng YT, Hsu CM, Yeh CT, Chiu CT (2016) Resistin reinforces interferon λ-3 to eliminate hepatitis C virus with fine-tuning from RETN single-nucleotide polymorphisms. Sci Rep 6:30799
Cheng S, Rhee EP, Larson MG, Lewis GD, McCabe EL, Shen D, Palma MJ, Roberts LD, Dejam A, Souza AL, Deik AA, Magnusson M, Fox CS, O’Donnell CJ, Vasan RS, Melander O, Clish CB, Gerszten RE, Wang TJ (2012) Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation 125:2222–2231
Clark PJ, Thompson AJ, Vock DM, Kratz LE, Tolun AA, Muir AJ, McHutchison JG, Subramanian M, Millington DM, Kelley RI, Patel K (2012) Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology 56:49–56
Dumas ME, Kinross J, Nicholson JK (2014) Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease. Gastroenterology 146:46–62
Fitian AI, Nelson DR, Liu C, Xu Y, Ararat M, Cabrera R (2014) Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS. Liver Int 34:1428–1444
Flydal MI, Martinez A (2013) Phenylalanine hydroxylase: function, structure, and regulation. IUBMB Life 65:341–349
Fultang L, Vardon A, De Santo C, Mussai F (2016) Molecular basis and current strategies of therapeutic arginine depletion for cancer. Int J Cancer 139:501–509
Holecek M (2015) Ammonia and amino acid profiles in liver cirrhosis: effects of variables leading to hepatic encephalopathy. Nutrition 31:14–20
Holm E, Sedlaczek O, Grips E (1999) Amino acid metabolism in liver disease. Curr Opin Clin Nutr Metab Care 2:47–53
Hoyo-Becerra C, Schlaak JF, Hermann DM (2014) Insights from interferon-α-related depression for the pathogenesis of depression associated with inflammation. Brain Behav Immun 42:222–231
Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY (2014) Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 59:1293–1302
Hu JH, Chen MY, Yeh CT, Lin HS, Lin MS, Huang TJ, Chang ML (2016) Sexual dimorphic metabolic alterations in hepatitis C virus-infected patients: a community-based study in a hepatitis b/hepatitis C virus hyperendemic area. Medicine (Baltimore) 95:e3546
Imae M, Asano T, Murakami S (2014) Potential role of taurine in the prevention of diabetes and metabolic syndrome. Amino Acids 46:81–88
Jung YS (2015) Metabolism of sulfur-containing amino acids in the liver: a link between hepatic injury and recovery. Biol Pharm Bull 38:971–974
Jungas RL, Halperin ML, Brosnan JT (1992) Quantitative analysis of amino acid oxidation and related gluconeogenesis in humans. Physiol Rev 72:419–448
Kawaguchi T, Izumi N, Charlton MR, Sata M (2011) Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology 54:1063–1070
Kawaguchi T, Torimura T, Takata A, Satomi S, Sata M (2012) Valine, a branched-chain amino Acid, reduced HCV viral load and led to eradication of HCV by interferon therapy in a decompensated cirrhotic patient. Case Rep Gastroenterol 6:660–667
Lin IC, Hsu CN, Lo MH, Chien SJ, Tain YL (2016) Low urinary citrulline/arginine ratio associated with blood pressure abnormalities and arterial stiffness in childhood chronic kidney disease. J Am Soc Hypertens 10:115–123
Lynch CJ, Adams SH (2014) Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol 10:723–736
Miller-Fleming L, Olin-Sandoval V, Campbell K, Ralser M (2015) Remaining mysteries of molecular biology: the role of polyamines in the cell. J Mol Biol 427:3389–3406
O’Mahony SM, Clarke G, Borre YE, Dinan TG, Cryan JF (2015) Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res 277:32–48
Papageorgiou N, Androulakis E, Papaioannou S, Antoniades C, Tousoulis D (2015) Homoarginine in the shadow of asymmetric dimethylarginine: from nitric oxide to cardiovascular disease. Amino Acids 47:1741–1750
Ramière C, Rodriguez J, Enache LS, Lotteau V, André P, Diaz O (2014) Activity of hexokinase is increased by its interaction with hepatitis C virus protein NS5A. J Virol 88:3246–3254
Roe B, Kensicki E, Mohney R, Hall WW (2011) Metabolomic profile of hepatitis C virus-infected hepatocytes. PLoS One 6:e23641
Rooks MG, Garrett WS (2016) Gut microbiota, metabolites and host immunity. Nat Rev Immunol 16:341–352
Saito T, Sugimoto M, Igarashi K, Saito K, Shao L, Katsumi T, Tomita K, Sato C, Okumoto K, Nishise Y, Watanabe H, Tomita M, Ueno Y, Soga T (2013) Dynamics of serum metabolites in patients with chronic hepatitis C receiving pegylated interferon plus ribavirin: a metabolomics analysis. Metabolism 62:1577–1586
Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457:910–914
Sugiyama K, Ebinuma H, Nakamoto N, Sakasegawa N, Murakami Y, Chu PS, Usui S, Ishibashi Y, Wakayama Y, Taniki N, Murata H, Saito Y, Fukasawa M, Saito K, Yamagishi Y, Wakita T, Takaku H, Hibi T, Saito H, Kanai T (2014) Prominent steatosis with hypermetabolism of the cell line permissive for years of infection with hepatitis C virus. PLoS One 9:e94460
Sun H, Zhang A, Yan G, Piao C, Li W, Sun C, Wu X, Li X, Chen Y, Wang X (2013) Metabolomic analysis of key regulatory metabolites in hepatitis C virus-infected tree shrews. Mol Cell Proteom 12:710–719
Toyoda H, Kumada T, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Ito T (2015) Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol 30:1183–1189
van Dyk M, Mangoni AA, McEvoy M, Attia JR, Sorich MJ, Rowland A (2015) Targeted arginine metabolomics: a rapid, simple UPLC-QToF-MS(E) based approach for assessing the involvement of arginine metabolism in human disease. Clin Chim Acta 447:59–65
Xiao D, Zeng L, Yao K, Kong X, Wu G, Yin Y (2016) The glutamine-alpha-ketoglutarate (AKG) metabolism and its nutritional implications. Amino Acids 48:2067–2080
Zangerle R, Kurz K, Neurauter G, Kitchen M, Sarcletti M, Fuchs D (2010) Increased blood phenylalanine to tyrosine ratio in HIV-1 infection and correction following effective antiretroviral therapy. Brain Behav Immun 24:403–408
Zhang AH, Sun H, Han Y, Yan GL, Yuan Y, Song GC, Yuan XX, Xie N, Wang XJ (2013) Ultraperformance liquid chromatography-mass spectrometry based comprehensive metabolomics combined with pattern recognition and network analysis methods for characterization of metabolites and metabolic pathways from biological data sets. Anal Chem 85:7606–7612
Acknowledgements
The authors thank Mr. Cheng-Yu Huang from Metabolomics Core Laboratory, Health Aging Research Center, Chang Gung University and Mr. Chun-Ming Fan from the Department of Biomedical Sciences, College of Medicine, Chang Gung University for their excellent figure generations and Ms. Shu-Chun Chen from the Liver Research Center, Chang Gung Memorial Hospital, Taiwan, for her data mining assistance.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Funding
This study was supported by grants from the Chang Gung Medical Research Program (CIRPG3D0121, CMRPG3F0471, CRRPG3F0011, CMRPG3B1743 and XMRPG3A0525) and from the National Science Council, Taiwan (102-2628-B-182-021-MY3, MOST 105-2314-B-182-023, and MOST 105-2629-B-182-001-).
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Handling Editor: C.-A. A. Hu.
Rights and permissions
About this article
Cite this article
Chang, ML., Cheng, ML., Chang, SW. et al. Recovery of pan-genotypic and genotype-specific amino acid alterations in chronic hepatitis C after viral clearance: transition at the crossroad of metabolism and immunity. Amino Acids 49, 291–302 (2017). https://doi.org/10.1007/s00726-016-2360-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-016-2360-7